Skip to Content

Tilray Earnings: Slower Revenue Growth and Margin Contraction

We’ve lowered our fair value estimate of Tilray’s stock.

Tilray corporate logo.

Key Morningstar Metrics for Tilray Brands

What We Thought of Tilray Brands’ Earnings

Tilray Brands TLRY issued disappointing results for the fiscal third quarter (February-ended) of 2024, including slower revenue growth and margin contraction. Changes to our forecast alone imply a valuation reduction roughly in line with the ensuing market price decline of about 21%. In addition, we’ve removed all contributions to our fair value estimate from Tilray’s ownership of US multistate operator Medmen’s senior secured convertible notes, as a complete write-off of the investment seems inevitable. The asset had made up about 20% of our fair value estimate.

Due to these factors, we are cutting our fair value estimate to $2. As reflected in our Very High Uncertainty Rating, changes to our forecast can have dramatic effects on our fair value estimates, especially as Tilray has yet to achieve positive free cash flow. Shares trade close to our updated fair value estimates.

Tilray reported net revenue of $188 million in the quarter, down 3% sequentially. The third quarter tends to be weak because of fewer cannabis and alcohol purchases during the winter. Still, the 5% sequential decline in cannabis revenue included some lost market share and price compression, driving us to lower our fiscal 2024 net revenue forecast to $755 million from $783 million and our adjusted EBITDA forecast to $60.5 million from $72.6 million.

Margin contraction was particularly worrisome, given that the third-quarter adjusted EBITDA margin of 5% was about half of last year’s third-quarter level. Some of the decline was because of dilution from recently acquired beer brands, and profitability should improve as capacity utilization increases. Even so, we’ve lowered our long-term adjusted EBITDA margin forecast to 20% from 23% to reflect margin differences across segments.

Tilray Brands Inc Stock Price

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Kristoffer Inton

Equity Strategist, Consumer
More from Author

Kristoffer Inton is an equity strategist, ESG, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He covers cannabis companies.

Before joining Morningstar in 2013, Inton was an investment banking associate for Guggenheim Securities in New York. Previously, he was an investment banking analyst for Merrill Lynch in Chicago and New York.

Inton holds a bachelor's degree in finance with high honors from the University of Illinois and a Master of Business Administration with distinction from Northwestern University's Kellogg School of Management.

Sponsor Center